# Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer

> **NCT02605811** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Medical University** · enrollment: 426 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Metastatic Carcinoma

## Interventions

- **DRUG:** temozolomide
- **RADIATION:** prophylaxis cranial radiotherapy

## Key facts

- **NCT ID:** NCT02605811
- **Lead sponsor:** Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2019-12
- **Final completion:** 2021-12
- **Target enrollment:** 426 (ESTIMATED)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605811, "Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02605811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*